{'Year': '2023', 'Month': 'Jun', 'Day': '20'}
[Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy].
To evaluate the value of pharmacogenetic testing for improving the efficacy and safety of treatment with cyclosporine, tacrolimus, and cyclophosphamide (CTX) for PLA2R-related membranous nephropathy and for determing individualized and precise treatment plans for the patients.